Vericel Corp 8-K

What Happened
Vericel Corporation announced preliminary, unaudited operating and financial results for fiscal year 2025 in a press release dated January 13, 2026, ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (11:15 a.m. PT). The company disclosed estimates for full-year 2025 revenue, net income, gross margin percentage, adjusted EBITDA margin, and its estimated cash and investments balance as of December 31, 2025. These figures are preliminary and the company warned they have not been finalized or audited.

Key Details

• Press release dated January 13, 2026 was furnished as Exhibit 99.1 to the Form 8-K.
• Vericel will present at the J.P. Morgan Healthcare Conference on January 14, 2026 at 11:15 a.m. PT.
• The release includes preliminary, unaudited estimates for: full-year 2025 revenue; 2025 net income; 2025 gross margin percentage; 2025 adjusted EBITDA margin; and estimated cash & investments as of 12/31/2025.
• The company cautioned these preliminary results are subject to change and actual results may differ materially; investors should not place undue reliance on them.

Why It Matters
This filing gives investors an early, unaudited view of Vericel’s fiscal 2025 performance and liquidity position ahead of audited results and formal filings. Because the numbers are preliminary and subject to revision, they should be treated as tentative indicators rather than final earnings or guidance. The update may influence near-term market reaction, but investors should wait for finalized audited financial statements for confirmation.